John Knopf, chief executive of Acceleron, said: "We're especially pleased with Celgene's commitment to Acceleron as we jointly develop several promising products for the treatment of anaemia."

US-based drugs group Acceleron Pharma has raised $30m from a consortium including peer Celgene following a partnership between the two companies to develop two drugs to treat a lack of iron in a person’s blood.

John Knopf, chief executive of Acceleron, said: "We’re especially pleased with Celgene’s commitment to Acceleron as we jointly develop several promising products for the treatment of anaemia."

Celgene granted Acceleron an up-front payment of $25m and the opportunity to earn $217m in milestone payments for rights…